JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB263903

Anti-IGF1 Receptor antibody [EPR23027-204]

  • 20ul selling size
  • BOND RX™ Validated
  • RabMAb
  • Recombinant
  • KO Validated
  • What is this?

Be the first to review this product! Submit a review

|

(7 Publications)

Knockout Tested Rabbit Recombinant Monoclonal IGF1 Receptor antibody. Suitable for WB, IHC-P and reacts with Human samples. Cited in 7 publications.

View Alternative Names

CD221, Insulin-like growth factor 1 receptor, Insulin-like growth factor I receptor, IGF-I receptor, IGF1R

6 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-IGF1 Receptor antibody [EPR23027-204] (AB263903)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-IGF1 Receptor antibody [EPR23027-204] (AB263903)

Immunohistochemical analysis of paraffin-embedded Human prostatic hyperplasia tissue labeling IGF1 Receptor with ab263903 at 1/500 dilution (1.24 ug/ml) followed by a ready to use Goat Anti-Rabbit IgG H&L (HRP Polymer). Membranous and cytoplasmic staining on human prostatic hyperplasia (PMID : 20710042). The section was incubated with ab263903 for 30 mins at RT. The immunostaining staining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin.

Secondary antibody only control : Secondary antibody is a ready to use Goat Anti-Rabbit IgG H&L (HRP Polymer).

Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution 2) for 20 mins.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-IGF1 Receptor antibody [EPR23027-204] (AB263903)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-IGF1 Receptor antibody [EPR23027-204] (AB263903)

Immunohistochemical analysis of paraffin-embedded Human bladder carcinoma tissue labeling IGF1 Receptor with ab263903 at 1/500 dilution (1.24 ug/ml) followed by a ready to use Goat Anti-Rabbit IgG H&L (HRP Polymer). Membranous and cytoplasmic staining on human bladder carcinoma (PMID : 20710042). The section was incubated with ab263903 for 30 mins at RT. The immunostaining staining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin.

Secondary antibody only control : Secondary antibody is a ready to use Goat Anti-Rabbit IgG H&L (HRP Polymer).

Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution 2) for 20 mins.

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-IGF1 Receptor antibody [EPR23027-204] (AB263903)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-IGF1 Receptor antibody [EPR23027-204] (AB263903)

Immunohistochemical analysis of paraffin-embedded Human breast carcinoma tissue labeling IGF1 Receptor with ab263903 at 1/500 dilution (1.24 ug/ml) followed by a ready to use Goat Anti-Rabbit IgG H&L (HRP Polymer). Membranous and cytoplasmic staining on human breast carcinoma (PMID : 21057462). The section was incubated with ab263903 for 30 mins at RT. The immunostaining staining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin.

Secondary antibody only control : Secondary antibody is a ready to use Goat Anti-Rabbit IgG H&L (HRP Polymer).

Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution 2) for 20 mins.

Western blot - Anti-IGF1 Receptor antibody [EPR23027-204] (AB263903)
  • WB

Unknown

Western blot - Anti-IGF1 Receptor antibody [EPR23027-204] (AB263903)

Blocking and dilution buffer : 5% NFDM/TBST.

Exposure time : 10 seconds.

The expression profile & molecular weight observed is consistent with what has been described in the literature (PMID : 21807868, 28591735).

Note : the bands larger than 200kDa are Pro-IGF1R

Low expression cell line : MDA-MB-231 (PMID : 28591735).

All lanes:

Western blot - Anti-IGF1 Receptor antibody [EPR23027-204] (ab263903) at 1/100000 dilution

Lane 1:

A431 (human epidermoid carcinoma epithelial cell) whole cell lysate at 20 µg

Lane 2:

HepG2 (human hepatocellular carcinoma epithelial cell) whole cell lysate at 20 µg

Lane 3:

HeLa (human cervix adenocarcinoma epithelial cell) whole cell lysate at 20 µg

Lane 4:

MDA-MB-231 (human breast adenocarcinoma epithelial cell) whole cell lysate at 20 µg

Predicted band size: 154 kDa

Observed band size: 130 kDa,200 kDa

false

Western blot - Anti-IGF1 Receptor antibody [EPR23027-204] (AB263903)
  • WB

Lab

Western blot - Anti-IGF1 Receptor antibody [EPR23027-204] (AB263903)

False colour image of Western blot : Anti-IGF1 Receptor antibody [EPR23027-204] staining at 1/1000 dilution, shown in green; Mouse anti-CANX [CANX/1543] (ab238078) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab263903 was shown to bind specifically to IGF1 Receptor. A band was observed at 105-125 kDa (alpha chain) in wild-type MCF7 cell lysates with no signal observed at this size in IGF1R knockout cell line. To generate this image, wild-type and IGF1R knockout MCF7 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in fluorescent western blot (TBS-based) blocking solution before incubation with primary antibodies overnight at 4°C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution.

All lanes:

Western blot - Anti-IGF1 Receptor antibody [EPR23027-204] (ab263903) at 1/1000 dilution

Lane 1:

Wild-type MCF7 cell lysate at 20 µg

Lane 2:

IGF1R knockout MCF7 cell lysate at 20 µg

Lane 3:

HeLa cell lysate at 20 µg

Lane 4:

HDLM-2 cell lysate at 20 µg

Observed band size: 105-125 kDa

false

Western blot - Anti-IGF1 Receptor antibody [EPR23027-204] (AB263903)
  • WB

Lab

Western blot - Anti-IGF1 Receptor antibody [EPR23027-204] (AB263903)

Anti-IGF1R antibody [EPR23027-204] (ab263903) staining at 1/1000 dilution, shown in green; Mouse anti-CANX [CANX/1543] (ab238078) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab263903 was shown to bind specifically to IGF1R. A band was observed at 105 kDa in wild-type HCT 116 cell lysates with no signal observed at this size in IGF1R knockout cell line. To generate this image, wild-type and IGF1R knockout HCT 116 cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in fluorescent western blot (TBS-based) blocking solution before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution.

All lanes:

Western blot - Anti-IGF1 Receptor antibody [EPR23027-204] (ab263903) at 1/1000 dilution

Lanes 1 - 4:

Western blot at 20 µg

Lane 2:

Western blot - Human IGF1R knockout HCT116 cell line (<a href='/en-us/products/cell-lines/human-igf1r-knockout-hct116-cell-line-ab287509'>ab287509</a>)

Secondary

All lanes:

Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution

Predicted band size: 154 kDa

Observed band size: 105 kDa

false

  • Carrier free

    Anti-IGF1 Receptor antibody [EPR23027-204] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR23027-204

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

IHC-P, WB

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "<p></p>", "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "<p></p>", "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/500", "IHCP-species-notes": "<p></p> Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol." }, "Mouse": { "IP-species-checked": "notRecommended", "IP-species-dilution-info": "", "IP-species-notes": "<p></p>", "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "<p></p>", "WB-species-checked": "notRecommended", "WB-species-dilution-info": "", "WB-species-notes": "", "ICCIF-species-checked": "notRecommended", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "<p></p>", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "" } } }

Product details

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Shipped at conditions
Conditional Ambient
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The IGF1 Receptor often referred to as IGF-1R is a transmembrane receptor protein composed of alpha and beta subunits. Studies indicate that the IGF1R protein is involved in mediating the effects of insulin-like growth factor 1 (IGF-1) and plays an important role in cellular signaling. It has a molecular weight of approximately 180 kDa and is widely expressed in various tissues with high concentrations in the liver muscle and brain. Being a tyrosine kinase receptor IGF1R plays an essential role in growth and metabolism.
Biological function summary

IGF1R contributes to several cellular processes including cell proliferation differentiation and survival. This receptor forms a complex upon ligand binding and undergoes autophosphorylation to activate intracellular signaling cascades. IGF1R activation recruits and phosphorylates insulin receptor substrates enabling the downstream signaling pathways that promote cell growth and survival. Its function in cellular responses makes it a focal point in understanding cell biology.

Pathways

IGF1R holds a central position in the PI3K/AKT and MAPK signaling cascades. These pathways play significant roles in cellular growth proliferation and survival. IGF1R phosphorylates various downstream effectors such as IRS-1 and Shc linking it to the activation of AKT and ERK respectively. Therefore it shares pathways with related proteins like the insulin receptor highlighting its importance in mediating similar biological responses.

IGF1R has been implicated in cancers and diabetes. Overexpression of IGF1R has been observed in various malignancies including breast cancer where it relates to resistance in treatment and poor prognosis with cell lines like MCF-7 often being studied in this context. Additionally disruptions in IGF1R signaling link to insulin resistance an important feature of type 2 diabetes. These connections make IGF1R a potential therapeutic target with IGF1R inhibitors currently under exploration to address these health challenges.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways : the PI3K-AKT/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K (PIK3R1), leading to activation of several downstream substrates, including protein AKT/PKB. AKT phosphorylation, in turn, enhances protein synthesis through mTOR activation and triggers the antiapoptotic effects of IGFIR through phosphorylation and inactivation of BAD. In parallel to PI3K-driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1 or Shc leads to recruitment of Ras and activation of the ras-MAPK pathway. In addition to these two main signaling pathways IGF1R signals also through the Janus kinase/signal transducer and activator of transcription pathway (JAK/STAT). Phosphorylation of JAK proteins can lead to phosphorylation/activation of signal transducers and activators of transcription (STAT) proteins. In particular activation of STAT3, may be essential for the transforming activity of IGF1R. The JAK/STAT pathway activates gene transcription and may be responsible for the transforming activity. JNK kinases can also be activated by the IGF1R. IGF1 exerts inhibiting activities on JNK activation via phosphorylation and inhibition of MAP3K5/ASK1, which is able to directly associate with the IGF1R.. When present in a hybrid receptor with INSR, binds IGF1. PubMed : 12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed : 16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.
See full target information IGF1R

Publications (7)

Recent publications for all applications. Explore the full list and refine your search

PloS one 19:e0313867 PubMed39570927

2024

Single-cell sequencing reveals transcriptional dynamics regulated by ERα in mouse ovaries.

Applications

Unspecified application

Species

Unspecified reactive species

Qicai Hu,Yiqian Gui,Congcong Cao,Jun Xie,Huiru Tang

European journal of histochemistry : EJH 67: PubMed37195011

2023

Metformin sensitises osteosarcoma to chemotherapy <em>via</em> the IGF-1R/miR-610/FEN1 pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Suwei Dong,Yanbin Xiao,Ziqiang Zhu,Xiang Ma,Zhuohui Peng,Jianping Kang,Jianqiang Wang,Yunqing Wang,Zhen Li

American journal of cancer research 13:569-588 PubMed36895975

2023

Identification and validation of the cellular senescence-related molecular subtypes of triple negative breast cancer via integrating bulk and single-cell RNA sequencing data.

Applications

Unspecified application

Species

Unspecified reactive species

Gaoda Ju,Kai Zeng,Linlin Lu,Han Diao,Hao Wang,Xiaomin Li,Tianhao Zhou

Biomedicines 11: PubMed36831107

2023

Progression of Thoracic Aortic Dissection Is Aggravated by the hsa_circ_0007386/miR-1271-5P/IGF1R/AKT Axis via Induction of Arterial Smooth Muscle Cell Apoptosis.

Applications

Unspecified application

Species

Unspecified reactive species

Xinsheng Xie,Xiang Hong,Shichai Hong,Yulong Huang,Gang Chen,Yihui Chen,Yue Lin,Weifeng Lu,Weiguo Fu,Lixin Wang

Frontiers in immunology 13:909324 PubMed35898507

2022

Immunogenomic Characteristics of Cell-Death-Associated Genes with Prognostic Implications in Bladder Cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Wenhao Xu,Hai-Jia Tang,Aihetaimujiang Anwaier,Wangrui Liu,Xi Tian,Jiaqi Su,Shiyin Wei,Yuanyuan Qu,Hailiang Zhang,Dingwei Ye

International journal of medical sciences 18:2814-2827 PubMed34220309

2021

Abnormal proinflammatory and stressor environmental with increased the regulatory cellular IGF-1/PAPP-A/STC and Wnt-1/β-Catenin canonical pathway in placenta of women with Chronic venous Disease during Pregnancy.

Applications

Unspecified application

Species

Unspecified reactive species

Miguel A Ortega,Oscar Fraile-Martínez,Miguel A Saez,Miguel A Álvarez-Mon,Ana M Gómez-Lahoz,Coral Bravo,Juan A De León Luis,Felipe Sainz,Santiago Coca,Ángel Asúnsolo,Jorge Monserrat,Luis G Guijarro,Melchor Álvarez-Mon,Julia Bujan,Natalio García-Honduvilla

BioMed research international 2020:6782659 PubMed33381575

2020

Chronic Venous Disease Patients Showed Altered Expression of IGF-1/PAPP-A/STC-2 Axis in the Vein Wall.

Applications

Unspecified application

Species

Unspecified reactive species

Miguel A Ortega,Oscar Fraile-Martínez,Ángel Asúnsolo,Clara Martínez-Vivero,Leonel Pekarek,Santiago Coca,Luis G Guijarro,Melchor Álvarez-Mon,Julia Buján,Natalio García-Honduvilla,Felipe Sainz
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com